Your Account
close button

Use our patient tools for secure, convenient, 24/7 access. Learn more


This facility is a member of

Connect with us:


A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma [ECOG 1609]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.